摘要
目的观察左西孟旦在高龄慢性心衰失代偿患者中的应用的安全性及临床疗效.方法选取年龄大于85岁的ADHF患者45例(心功能均为Ⅲ~Ⅳ级,LVEF≤40%,血浆NT-Pro BNP≥500μg/L),试验组23例,给予左西孟旦治疗,对照组22例,给予多巴酚丁胺治疗.观察2组患者用药前后生命体征、全身临床状况、LVEF、血浆NT-Pro BNP的变化.结果用药前2组患者一般状况差异无统计学意义(P>0.05);用药后不同时间点,试验组患者在缓解心衰临床状况、提高LVEF、降低血浆NT-Pro BNP较对照组差异有统计学意义(P<0.05或P<0.01),不良反应的发生率试验组22.7%、对照组42.9%,均无严重不良反应.结论左西孟旦可改善高龄ADHF患者心衰症状,提高心功能级别,安全有效,无严重不良反应.
Objective To observe the safety and clinical effect of the application of levosimendanin to advanced aged patients with acute decompensated chronic heart failure. Method 45 acute decompensated chronic heart failure patients more than 85 years old with low cardiac output （Cardiac function ： Ⅲ- Ⅳ level , left ventricular ejective fraction ≤ 40% and high blood plasma NT-ProBNP ≥ 500 ug/L）, experimental group （23 cases） were given levosimendan treatment, and control group （22 cases） were given dobutamine treatment. Vital signs, general clinical status, LVEF, and blood plasma NT-ProBNP changes were monitored before and after drug use. Results No statistical difference between the two groups was observed before treatment （P〉0.05） . At different time points after treatment, compared with the control group, the experimental group were statistically significant （P〈0.05 or P〈0.01） in relieving clinical status of heart failure, raising LVEF and reducing blood plasma NT-ProBNP.Incidence of adverse reactions is 22.7% in the experimental group and 42.9% in the control group, no serious adverse reactions in either group. Conclusion Levosimendan can improve heart failure symptoms, raise heart function level in advanced aged patients with acute decompensated chronic heart failure. It is safe and effective with no serious adverse reactions.
出处
《昆明医科大学学报》
CAS
2017年第2期78-81,共4页
Journal of Kunming Medical University
基金
云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目(2015UH00417)
关键词
高龄
慢性心衰急性失代偿
左西孟旦
Aged
Acute decompensated chronic heart failure
Levosimendan
